General description
We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1G4 is a ZooMAb® rabbit recombinant monoclonal antibody that specifically detects Tenascin. It targets an epitope within 20 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 20 amino acids from the C-terminal region of human Tenascin.
Application
Quality Control Testing
Evaluated by Western Blotting in SK-MEL-28 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected Tenascin in SK-MEL-28 cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected Tenascin in lysates from C6 cells and Mouse brain tissue and 1:10,000 dilution in Human brain tissue.
Affinity Binding Assay: A representative lot of this antibody bound Tenascin peptide with a KD of 1.7 x 10-7KD of 1.7 x 10-7 in an affinity binding assay.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected Tenascin in Human uterus and Mouse embryonic tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Tenascin (UniProt: P24821; also known as TN, Cytotactin, GMEM, GP 150-225, Glioma-associated-extracellular matrix antigen, Hexabrachion, JI, Myotendinous antigen, Neuronectin, Tenascin-C, TN-C) is encoded by the TNC (also known as HXB) gene (Gene ID: 3371) in human. Tenascins are a family of large multimeric extracellular matrix (ECM) proteins. In vertebrates four types of tenascins have been described: C, -R, -X and -W and each of these have a specific expression pattern. They are synthesized primarily by cells in connective tissues. However, each of the tenascins has a typical expression pattern that differs from all other tenascins. Tenascin-C is a highly conserved protein that is present in the central nervous system and is a prominent constituent of peripheral nerves. It is implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity, and neuronal regeneration. It also promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. It inhibits cell adhesion of many cell types to fibronectin. Tenascin-C is a hexameric, multimodular ECM protein with several molecular forms that are created through alternative splicing and protein modifications. It is synthesized with a signal peptide (aa 1-22) that is subsequently cleaved off in the mature protein. It contains heptad repeats near its N-terminus that support trimerization and two trimers can join to form a hexabrachion. The heptad repeats are followed from N- to C-terminus by one or more EGF-like domains, a string of fibronectin-type III repeats and a fibrinogen-like globe. This multimodular structure enables it to interact with a high number of highly diverse ligands. Tenascin-C is highly induced by infections and inflammation and tenascin-C knockout mouse exhibit reduced inflammatory response. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Midwood, KS., et al. (2016). J. Cell Sci. 129(23); 4321-4327; Chiquet-Ehrismann, R. (2004). Int. J. Biochem. Cell Biol. 36(6); 986-990).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.